# NUV 2 4 2009

# 7 510(k) Summary

# K092104

<table><tr><td rowspan=1 colspan=1>Submitter:</td><td rowspan=1 colspan=1>ARKRAY Factory USA, Inc.5182 W. 76th StreetMinneapolis, MN 55439</td></tr><tr><td rowspan=1 colspan=1>Contact Person:</td><td rowspan=1 colspan=1>Hamid IdrissiRegulatory Affairs Project ManagerARKRAY Factory USA, Inc.5182 W. 76th StreetMinneapolis, MN 55439Phone: 952-646-3171Fax: 952-646-3110idrissih@ARKRAYusa.com</td></tr><tr><td rowspan=1 colspan=1>Date Prepared:</td><td rowspan=1 colspan=1>July 10, 2009</td></tr><tr><td rowspan=1 colspan=1>Trade Name:</td><td rowspan=1 colspan=1>Assure Platinum Blood Glucose Monitoring System</td></tr><tr><td rowspan=1 colspan=1>Classification:</td><td rowspan=1 colspan=1>Glucose test system, 21 CFR 862.1345 and 862.1660; Class f</td></tr><tr><td rowspan=1 colspan=1>Product Codes:</td><td rowspan=1 colspan=1>CGA, NBW, JJX</td></tr><tr><td rowspan=1 colspan=1>Predicate Device:</td><td rowspan=1 colspan=1>Assure Pro (k053079)</td></tr><tr><td rowspan=1 colspan=1>Device Description:</td><td rowspan=1 colspan=1>The Assure Platinum Blood Glucose Monitoring System consist of ameter, test strips, and control solution for use as an aid to monitor theeffectiveness of diabetes control.</td></tr><tr><td rowspan=1 colspan=1>Intended Use:</td><td rowspan=1 colspan=1>The Assure Platinum Blood Glucose Monitoring Systems is intendedfor the quantitative measurement of glucose in fresh capillary wholeblood samples drawn from the fingertips. Testing is done outside thebody (In Vitro diagnostic use). It is indicated for use at home (over thecounter [OTC]) by persons with diabetes, or in clinical settings byhealthcare professionals, as an aid to monitor the effectiveness ofdiabetes control.The Assure Platinum Blood Glucose Monitoring System is not intendedfor the diagnosis of or screening for diabetes mellitus, and is notintended for use on neonates.</td></tr><tr><td rowspan=1 colspan=1>Functional andSafety Testing:</td><td rowspan=1 colspan=1>A full array of in-house and clinical testing was done consistent withrelevant FDA guidance&#x27;s for blood glucose monitoring systems.Bench testing included evaluation of interferences, Dynamic range andlinearity, hematocrit effects, altitude effects, control solutionfunctionality, and analytical precision.Clinical testing included evaluation of accuracy for finger stick forAssure Platinum.</td></tr><tr><td rowspan=1 colspan=1>Conclusion:</td><td rowspan=1 colspan=1>Labeling, bench testing results and clinical testing results support theIndications for Use and the claim of substantial equivalence to thepredicate.</td></tr></table>

# NOV Z 4 2009

Arkray Factory USA, Inc.   
c/o Mr. Hamid Idrissi   
Regulatory Affairs Project Manager 5182 W. $\dot { 7 } 6 ^ { \mathfrak { q } }$ Street   
Minneapolis, MN 55439

Re: k092104 Trade Name: Assure Platinum Blood Glucoses Monitoring System Regulation Number: 21 CFR $\ S 8 6 2 . 1 3 4 5$ Regulation Name: Glucose test system Regulatory Class: Class II Product Codes: CGA, NBW, JJX Dated: November 04, 2009 Received: November 16, 2009

Dear Mr. Idrissi:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) thatÂ·do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21; Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (301) 796-5760. For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or ( 301 ) 796-5680 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

![](images/1ed8b825d53bd182bce1adfe0cdf23a37f9bf3bca56042fb56162fa5f2754a30.jpg)

Courtny C. Harper, Ph.D.   
Director   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

Enclosure

# 6 Indications for Use Statement

510k be) K092104

Device Name: Assure Platinum Blood Glucose Monitoring System

Indications For Use:

Assure Platinum Blood Glucose Monitoring System:

The Assure Platinum Blood Glucose Monitoring System is intended for the quantitative measurement of glucose in fresh capillary whole blood samples drawn from the fingertips. Testing is done outside the boy (In Vitro diagnosticuse).It is indicated for use at home (over the counter [OC]) by persons wth diabetes, or in clinical settings by healthcare professionals, as an aid to monitor the effectiveness of diabetes control.

The Assure Platinum Blood Glucose Monitoring Systemsot intended orhe diagnosis  rscreen for diabetes mellitus, and is not intended for use on neonates.

Assure Platinum Blood Glucose Meter:

The Assure Platinum Blood Glucose Meter is intended for the quantitative measurement of glucose in fr capillary whole blood samples drawn from the fingertips.Testing is done outside the body nVi dianosicuse). It is indicated for use at home (over the counter [C]) by persons with diabetes, n clinical settings by healthcare professionals, as an aid to monitor the effectiveness of diabetes control.

Assure Platinum Blood Glucose Test Strips:

Assure Platinum test strips are intended for the quantitative measurement of glucose in fresh capillary whole blood samples drawn from the fingertips when used with the Assure Platinum Blood Glucose Meter.Testing is done outside the body In Vitro diagnostic use.They are indicated for use inhome (over the counter [OTC]) by persons with diabetes, or in clinical settings by healthcare professionals, as an aid to monitor the effectiveness of diabetes control.

Assure Dose COnTROL:   
Foruse with Assure Platinum Blood Glucose Meter and Assure Platinum Blood Glucose Test Strips as a quality control check vecray blgucoe  resusCnolsoluns va two levels - Normal (Level 1) and High (Level 2).

(cption U AND/OR (2ve-The-Couster Usc) X